Bret A. Witter, MD, FACC, FACP

Cardiovascular Diseases and Echocardiography

• Certified Echocardiography
  National Board of Echocardiography
  2012
• Certified in Cardiovascular Disease
  American Board of Internal Medicine
  November 1993 (Recertifications: 2003 and 2013)
• Certified in Internal Medicine
  American Board of Internal Medicine
  1990 (Recertifications: 2000 and 2009)
• FLEX (Federal Licensing Examination)
  Part 1: 1985 | Part 2: 1986
• National Boards (Taken Individually)
  1984 – 1987
• NASPE Testamur (Exam)
  North American Society of Pacing and Electrophysiology
  1998

• English
• Medical Spanish

• Los Alamitos Medical Center
  3751 Katella Avenue
  Los Alamitos, California 90720
• Long Beach Memorial Medical Center
  2801 Atlantic Avenue
  Long Beach, California 90806

Los Alamitos Medical Center

• Chairman, Pharmacy and Therapeutics, 2008 – 2014

St. Mary Medical Center

• Vice Chief of Medicine, 2002 – 2003
• Medical Director of Cardiopulmonary Unit, 2003
• Pharmacy and Therapeutics, 2001 – 2002
• Cardiac Catheterization/Cardiac Surgery Committee, 1996 – 2003
• Cardiac Catheterization/Cardiac Surgery Committee,1996 – 2000
• CCU/ICU Committee, 1994

MemorialCare Health System
Community Hospital Long Beach

• Chairman, Cardiac Advisory Board, 1996 – 1998

• American College of Physicians (FACP)
  Fellow: February 2002
• American College of Cardiology (FACC)
  Fellow: May 1995
• Los Angeles County Medical Association
  Member: 1995 – Present
• American College of Cardiology
  Member: 1990 – Present
• American College of Physicians
  Member: 1987 – Present

• Assistant Clinical Professor
  David Geffen School of Medicine
  University of California, Los Angeles (UCLA)
  1996 – 2018

• Los Alamitos Cardiovascular
  Los Alamitos, California
  October 1993 – Present
• Cardiovascular Associates
  Long Beach, California
  July 1993 – October 1993

• Cardiology Conference
  St. Mary Medical Center Long Beach
  2007 – Present
• ICU Morning Report
  St. Mary Medical Center Long Beach
  1993 – 2003, 2007 – 2009
• CCU/Cardiology Rounds
  St. Mary Medical Center Long Beach
  1993 – 2003

• Special Recognition for Teaching Excellence
  St. Mary Medical Center  Long Beach
  2003 – 2004
• Outstanding Teaching Physician
  St. Mary Medical Center Long Beach
  2000 – 2001
• Outstanding Teaching Physician
  St. Mary Medical Center Long Beach
  1993 – 1994

• “Differentiation of Cardiac and non Cardiac chest pain.”
  CARDIOLOGY 2000 symposium at Long Beach, California Hyatt,
  May 13, 2000
• “Transesophageal Echocardiography in the Critical care Setting.”
  CRITICAL CARE TRIAD, St. Mary Medical Center Long Beach,
  January 19, 1995

• Witter BA, Decristofaro D. “Muscle Bands, Tendons and Trabeculations.” (Letter) Am J. Cardiol. 1992; 71:499 – 500.

• Cardiovascular Diseases Fellowship
  St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
  Long Beach, California
  July 1990 – June 1993
• Internal Medicine Residency
  St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
  Long Beach, California
  July 1988 – June 1990
• Internal Medicine Internship
  St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
  Long Beach, California
  July 1987 –  June 1988
• Medical Education
  Baylor College of Medicine
  Houston, Texas
  August 1983 – June 1987
• Undergraduate Education
  Biological Sciences
  University of California, Irvine (UCI)
  Irvine, California
  September 1979 – June 1983

• Phi Beta Kappa
  Magna Cum Laude
  University of California, Irvine 1983

• AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
  Sub-Investigator | 2019
  Sponsor: CSL Behring LLC
  NCT03473223
• COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
  Sub-Investigator | 2018 – Present
  Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  NCT03196349
• NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03464019
• NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03635996
• PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
  Sub-Investigator | 2018 – Present
  Sponsor: Novartis
  NCT02924727
• PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
  Sub-Investigator | 2018 – Present
  Sponsor: Eko Devices
• GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  Sub-Investigator | 2017 – Present
  Sponsor: Amgen
  NCT02929329
• PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
  Sub-Investigator | 2017 – 2019
  Sponsor: Novartis
  NCT02887183
• Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
  Sub-Investigator | 2016 – Present
  Sponsor: CVRx, Inc.
  NCT02627196
• MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
  Sub-Investigator | 2016 – 2017
  Sponsor: Gilead/ICON
• THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
  Sub-Investigator | 2015 – Present
  Sponsor: AstraZeneca
  NCT01991795
• Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
  Sub-Investigator | 2015 – 2016
  Sponsor: Amgen, Evidera
• DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
  Sub-Investigator | 2013 – 2018
  Sponsor: AstraZeneca
  NCT01730534
• ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
  Sub-Investigator | 2013 – 2017
  Sponsor: Sanofi
  NCT01663402
• SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
  Sub-Investigator | 2013 – 2017
  Sponsor: Yale University School of Medicine/NIH
  NCT01755052
• RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
  Sub-Investigator | 2013– 2014
  Sponsor:  Janssen Scientific Affairs/Johnson & Johnson
• Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
  Sub-Investigator | 2013
  Sponsor: Tasly Pharmaceuticals
  NCT0169580
• Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
  Sub-Investigator | 2013 – 2018
  Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
  NCT01594333
• User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
  Sub-Investigator | 2012
  Sponsor: Alere San Diego
• Mission® PT Coagulation Monitoring System Clinical Study.
  Principal Investigator | 2012
  Sponsor: ACON Laboratories, INC
• The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
  Sub-Investigator | 2012 – 2015
  Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
  NCT00786474
• GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
  Sub-Investigator | 2012 – Present
  Sponsor: Boehringer Ingelheim
  NCT01468701
• BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
  Sub-Investigator | 2010 – 2012
  Sponsor: St. Jude Medical Center
  NCT01062126
• The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
  Sub-Investigator | 2010 – 2014
  Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
  NCT01174550
• ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
  Sub-Investigator | 2010 – 2017
  Sponsor: Janssen Scientific Affairs, LLC
  Collaborator: Duke Clinical Research
  NCT01165710 & NCT01701817
• RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
  Principal Investigator | 2008 – 2010
  Sponsor: St. Jude Medical Center
  NCT00837798
• FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
  Sub-Investigator | 2008 – 2010
  Sponsor: St. Jude Medical Center
  NCT00418314
• SAFE (Silent Atrial Fibrillation Detection with Stored EGMS).
  Sponsor: Guidant Corporation
• ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
  Sub-Investigator | 2009 – 2015
  Sponsor: Daiichi Sankyo Pharma Development
  NCT00781391
• Fosiniopril Drug Study.
  Sub-Investigator | 1992
  Sponsor: Bristol- Myers Squibb Company
• Supine Bike/Stress Echo (Unpublished).
  A.S. Abbasi, MD, FACC
  Long Beach, California
• Molecular Biology/ Immunology Cell Culture, electrophoresis techniques, 1978 – 1979. Gale Granger, PhD
  University of California, Irvine